Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,387,168
  • Shares Outstanding, K 27,688
  • Annual Sales, $ 91,280 K
  • Annual Income, $ -145,230 K
  • EBIT $ -29 M
  • EBITDA $ -37 M
  • 60-Month Beta 0.29
  • Price/Sales 15.17
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 64.47% (+1.37%)
  • Historical Volatility 37.04%
  • IV Percentile 4%
  • IV Rank 3.16%
  • IV High 218.29% on 02/10/25
  • IV Low 59.45% on 12/22/25
  • Expected Move (DTE 19) 5.23 (10.43%)
  • Put/Call Vol Ratio 38.00
  • Today's Volume 234
  • Volume Avg (30-Day) 382
  • Put/Call OI Ratio 1.18
  • Today's Open Interest 9,803
  • Open Int (30-Day) 18,077
  • Expected Range 44.87 to 55.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.89
  • Number of Estimates 8
  • High Estimate 2.21
  • Low Estimate -0.99
  • Prior Year -0.72
  • Growth Rate Est. (year over year) +223.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.01 +25.22%
on 12/01/25
51.43 -2.59%
on 12/22/25
+7.94 (+18.83%)
since 11/26/25
3-Month
23.15 +116.41%
on 09/29/25
51.43 -2.59%
on 12/22/25
+26.52 (+112.47%)
since 09/26/25
52-Week
12.21 +310.32%
on 02/11/25
51.43 -2.59%
on 12/22/25
+36.36 (+264.63%)
since 12/26/24

Most Recent Stories

More News
This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving

AnaptysBio (ANAB) has surged 227% over the past year, hitting a 5-year high. Shares have strong technical momentum and a 100% “Buy” opinion from Barchart. Analyst sentiment remains bullish, but Wall...

ANAB : 50.10 (+0.18%)
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration...

ANAB : 50.10 (+0.18%)
VNDA : 7.04 (+1.88%)
Anaptys Announces Participation in December Investor Conferences

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 50.10 (+0.18%)
Anaptys Announces $100 Million Stock Repurchase Plan

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its...

ANAB : 50.10 (+0.18%)
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a...

ANAB : 50.10 (+0.18%)
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Rosnilimab was safe and well tolerated with similar adverse event rates vs . placebo Observed expected pharmacology, including ~90% depletion of pathogenic T cells, however lack of adequate efficacy...

ANAB : 50.10 (+0.18%)
Anaptys Announces Participation in November Investor Conferences

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 50.10 (+0.18%)
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Announced intent to separate biopharma operations from substantial royalty assets by YE 2026 Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on...

ANAB : 50.10 (+0.18%)
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy,...

ANAB : 50.10 (+0.18%)
Truist Financial Reaffirms Their Hold Rating on AnaptysBio (ANAB)

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on AnaptysBio. The company’s shares closed yesterday at $31.85.Elevate Your Investing Strategy: Take advantage of TipRanks...

ANAB : 50.10 (+0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 51.02
2nd Resistance Point 50.60
1st Resistance Point 50.35
Last Price 50.10
1st Support Level 49.67
2nd Support Level 49.25
3rd Support Level 49.00

See More

52-Week High 51.43
Last Price 50.10
Fibonacci 61.8% 36.45
Fibonacci 50% 31.82
Fibonacci 38.2% 27.19
52-Week Low 12.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar